Company profile: NextPoint Therapeutics
1.1 - Company Overview
Company description
- Provider of clinical-stage therapeutics to treat cancer, including NPX887 targeting HHLA2 and NPX267 targeting KIR3DL3 to reactivate exhausted T and NK cells in HHLA2+ solid tumors.
Products and services
- Cancer Therapeutics Development: Clinical-stage oncology program engineers therapeutics to reactivate exhausted T and NK cells in HHLA2+ solid tumors via HHLA2 and KIR3DL3 targets
- Clinical-stage
- NPX267: Therapeutic targeting KIR3DL3 to reactivate exhausted T and NK cells in HHLA2+ solid tumors, with activity specified for HHLA2+ solid tumors
- KIR3DL3-specific
- NPX887: Therapeutic targeting HHLA2 to reactivate exhausted T and NK cells in HHLA2+ solid tumors, with activity defined in HHLA2+ solid tumors
- HHLA2-specific
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to NextPoint Therapeutics
ISA Pharmaceuticals
HQ: The Netherlands
Website
- Description: Provider of clinical-stage, fully synthetic immunotherapeutics and therapeutic vaccines for cancer and persistent viral infections, built on its Synthetic Long Peptide (SLP®) and AMPLIVANT® platforms; products include ISA101b for HPV16-induced cancers and ISA104 for chronic hepatitis B infections.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full ISA Pharmaceuticals company profile →
Intercell
HQ: Austria
Website
- Description: Provider of vaccine design and development for prevention and treatment of infectious diseases, leveraging proprietary technology platforms to discover and develop antigens and adjuvants. Founded in 1998 and headquartered in Vienna, Austria.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Intercell company profile →
Cue Biopharma
HQ: United States
Website
- Description: Provider of biologic immunotherapies and a platform for cancer, chronic viral infections, and autoimmune diseases. Offerings include CUE-101 activating tumor-specific T cells against HPV16+ head and neck cancer; CUE-102/103 targeting additional tumor antigens and HLA alleles in solid tumors; CUE-200 activating virus-specific CD8+ T cells; CUE-300 inhibiting autoreactive CD4+ and enhancing regulatory T cells; CUE-301 for type 1 diabetes.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Cue Biopharma company profile →
Vaccinogen
HQ: United States
Website
- Description: Provider of vaccines and other immunotherapeutic products for cancers and infectious diseases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Vaccinogen company profile →
VaxGen
HQ: United States
Website
- Description: Provider of biopharmaceutical products in the United States.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full VaxGen company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for NextPoint Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to NextPoint Therapeutics
2.2 - Growth funds investing in similar companies to NextPoint Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for NextPoint Therapeutics
4.2 - Public trading comparable groups for NextPoint Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →